Arcturus and CSL Seqirus terminate sa-mRNA vaccine partnership
Arcturus Therapeutics (Nasdaq: ARCT) terminated its sa-mRNA vaccine partnership with CSL Seqirus via a settlement. Arcturus regained global rights to KOSTAIVE (ARCT-154) and other vaccine programs. CSL Seqirus will pay $12m cash, and Arcturus is released from about $16m in R&D credits, totaling about $28m. The deal unwinds a pact valued around $4.3b.
How this was made
The 30-second read
Why it matters
The termination unwinds the original multi-billion-dollar structure and returns approved KOSTAIVE-related rights to Arcturus, with a defined settlement value (cash plus liability release) but increased commercialization responsibility in EU and Japan beyond the transitional Meiji Seika arrangement.
Market read
Traders may reassess Arcturus’s near-term cash flow and commercialization risk after the partnership unwind, especially for EU and Japan marketing authorizations tied to KOSTAIVE.
What to watch
Japan rights for 2026-2027 remain carved out with Meiji Seika, so the immediate commercialization gap may be smaller than implied; also, the company’s stated priority is ARCT-032 Phase III, which could redirect investor focus away from KOSTAIVE.
Background
Arcturus and CSL Seqirus had a December 2022 collaboration granting CSL Seqirus an exclusive global license to Arcturus’s STARR sa-mRNA and LUNAR delivery platforms across multiple vaccine targets, with upfront and milestone commitments.
Ticker impact
Arcturus terminated its sa-mRNA collaboration with CSL Seqirus, reverting global rights to KOSTAIVE and related vaccine programs.
Likely near-term volatility driven by uncertainty over KOSTAIVE commercialization and the size/timing of any new partnering, partially offset by the settlement cash and liability release.
The article provides settlement terms ($12M cash, ~$16M R&D credit liability release) and states KOSTAIVE marketing authorizations are now without a commercial partner in EU/Japan beyond a transitional arrangement, which can affect valuation and expectations for future milestones.
Market effects
Highlights ongoing commercial headwinds for COVID-19 vaccine programs and potential de-risking of sa-mRNA platform economics.
EU and Japan commercialization plans for KOSTAIVE shift back to Arcturus, increasing execution risk in those jurisdictions.
Reversion of a multi-billion-dollar sa-mRNA deal underscores broader demand compression for COVID vaccines globally.
Counterpoint
The settlement effectively monetizes part of the sa-mRNA asset base now, and Arcturus may re-partner KOSTAIVE later at better terms given the reduced milestone burden.
Key entities
- companyArcturus Therapeutics
Terminated the sa-mRNA collaboration with CSL Seqirus via settlement, regaining rights to KOSTAIVE and other vaccine programs.
- companyCSL Seqirus
Vaccine division of CSL Limited that will pay Arcturus $12M and resolve an arbitration dispute tied to a European regulatory milestone.
- companyCSL Limited
Parent of CSL Seqirus; not directly disclosed as the rationale for termination in the article.
- companyMeiji Seika Pharma
Holds transitional carve-out arrangements for Japan rights for the 2026-2027 season.
- companyThermo Fisher Scientific
Announced July 2026 collaboration to support Phase III development of ARCT-032, cited as Arcturus’s primary execution priority.
